Post Authorisation Safety Study With Raxone in LHON Patients

Launched by SANTHERA PHARMACEUTICALS · May 10, 2016

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient prescribed Raxone® for the treatment of LHON;
• • Patient has completed an Informed Consent Form (ICF) indicating that he/she (or a legally acceptable representative) has been informed of all pertinent aspects of the study and has agreed to participate in the study;
• • Patient is not participating in any interventional study.
• Exclusion Criteria:
• • No explicit exclusion criteria exist to avoid selection bias and to allow for documentation of routine clinical practice.